Q3 Earnings Estimate for RenovoRx Issued By HC Wainwright

RenovoRx, Inc. (NASDAQ:RNXT) – Equities researchers at HC Wainwright issued their Q3 2027 earnings per share (EPS) estimates for shares of RenovoRx in a research note issued on Friday, August 14th. HC Wainwright analyst S. Ramakanth forecasts that the company will post earnings per share of ($0.01) for the quarter. The consensus estimate for RenovoRx’s current full-year earnings is ($0.25) per share.

RenovoRx (NASDAQ:RNXT) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.02. The business had revenue of $0.91 million during the quarter, compared to the consensus estimate of $0.70 million. RenovoRx had a negative return on equity of 138.07% and a negative net margin of 621.71%.

Several other research firms have also recently weighed in on RNXT. Wall Street Zen raised shares of RenovoRx from a “sell” rating to a “hold” rating in a research note on Saturday. Ascendiant Capital Markets boosted their price target on shares of RenovoRx from $13.50 to $14.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Finally, Weiss Ratings raised shares of RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, RenovoRx has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

RenovoRx Stock Performance

RNXT stock opened at $1.17 on Monday. RenovoRx has a one year low of $0.70 and a one year high of $1.50. The company’s fifty day moving average price is $0.97 and its 200-day moving average price is $0.94. The company has a market capitalization of $52.71 million, a PE ratio of -3.77 and a beta of 0.99.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. AIGH Capital Management LLC raised its stake in RenovoRx by 30.8% during the first quarter. AIGH Capital Management LLC now owns 3,706,197 shares of the company’s stock valued at $3,682,000 after purchasing an additional 872,303 shares in the last quarter. Wealthspire Advisors LLC bought a new stake in shares of RenovoRx in the 4th quarter worth about $212,000. Citadel Advisors LLC purchased a new stake in shares of RenovoRx during the 3rd quarter valued at about $154,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of RenovoRx in the 2nd quarter valued at about $98,000. Finally, Bleichroeder LP lifted its holdings in shares of RenovoRx by 11.4% in the 4th quarter. Bleichroeder LP now owns 600,000 shares of the company’s stock valued at $504,000 after acquiring an additional 61,379 shares during the last quarter. 3.10% of the stock is currently owned by institutional investors.

Key Stories Impacting RenovoRx

Here are the key news stories impacting RenovoRx this week:

• Positive Sentiment: HC Wainwright raised its projected losses for both the third and fourth quarters of 2026 to $0.03 per share from $0.08, implying better-than-previously-expected near-term profitability. The firm also improved its FY2026 forecast to a $0.21-per-share loss from $0.33, compared with the broader consensus estimate of a $0.31 loss. Q3 Earnings Estimate for RenovoRx Issued By HC Wainwright
• Neutral Sentiment: The analyst continues to forecast a $0.04-per-share loss for FY2027, followed by projected profits of $0.08 in FY2028, $0.18 in FY2029 and $0.26 in FY2030. These estimates suggest a potential path toward profitability, but the timing and magnitude remain uncertain.
• Negative Sentiment: HC Wainwright reduced its longer-term earnings forecasts across FY2027 through FY2030: FY2027 was lowered from a $0.02 loss to a $0.04 loss, FY2028 was cut from $0.20 to $0.08, FY2029 from $0.31 to $0.18, and FY2030 from $0.42 to $0.26. The reductions indicate weaker expected earnings power than previously anticipated and may limit investor enthusiasm despite the improved 2026 outlook.

About RenovoRx

RenovoRx, Inc is a clinical-stage medical technology company focused on the development of proprietary drug-device combination therapies for the treatment of solid tumor malignancies. The company’s lead product candidate, RenovoCath™, is an intra-arterial catheter system designed to deliver high concentrations of chemotherapeutic agents directly to tumor sites while minimizing systemic exposure. RenovoRx seeks to improve clinical outcomes and reduce adverse effects by enhancing drug delivery precision in hard-to-treat cancers.

RenovoCath™ is being evaluated in multiple clinical trials targeting advanced pancreatic cancer and metastatic colorectal cancer, among other solid tumors.